Abhishek Asthana YOU? Author Swipe

Last 10y

Millets: A Nutrient - Rich Path to Sustainable Development Goals, Bridging the Gap Between Environment and Health Open

Shankar Deshpande, Abhishek Asthana · 2024

In 2015, the United Nations introduced the Sustainable Development Goals (SDGs), also known as the Global Goals. Another major company significantly contributes to these goals. In 2015, global leaders united to embrace the 2030 Agenda for …

Figure 2S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 2 BAFF induces up-regulation of survival pathways. A, PT-3 ALL cells were cultured with VAY736 (20 ÃŽÂ¼g/mL) and recombinant BAFF (0.2 ÃŽÂ¼g/mL) for 72 hours and the expression levels of proliferation genes (p100, p52) and survi…

Figure 4S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 4 Detection of NK cells in vivo A, Representative Dot plots of gated live cells based on FSCÃ,ÂA and SSCÃ,ÂA and CD19+CD10+ cells in the bone marrow and spleen of NSG mice treated with PBS (left) or 2x106 PTÃ,Â3 ALL cells (ri…

Figure 1S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 1 ALL sample characteristics. A, Summary data from 11 adults and 5 pediatric ALL patients. Genetic and diagnostic information was provided by clinical pathologist Rose Beck at University Hospitals Medical Center (UHMC). BAFF-R e…

Figure 3S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 3 Differential NK cells receptor expression A, Expression of activating and inhibitory receptors in NK cells expanded from the indicated healthy donors (mean {plus minus} SD of 3 technical replicates). B, Expression of HLAE and …

Figure 1S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 1 ALL sample characteristics. A, Summary data from 11 adults and 5 pediatric ALL patients. Genetic and diagnostic information was provided by clinical pathologist Rose Beck at University Hospitals Medical Center (UHMC). BAFF-R e…

Data from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies. Our study exploited the presence of B-cell activating factor receptor (BAFF-…

Figure 6S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 6 EW-7197 treatment increases VAY736 induced NK cell mediated ADCC of ALL cells in vivo A, Percentages of CD16+ NK cells in bone marrow and spleen of mice from Figure.6C-E. B, Normalized weight in grams (spleen weight/mouse weig…

Figure 5S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 5 EW-7197 treatment increases VAY736 induced NK cell mediated ADCC of ALL cells in vivo A, Mouse TGF-beta Elisa using serum from PBS or ALL (PT-3) i.v. injected mice on day 35. B, Normalized weight (spleen weight/mouse weight) a…

Supplementary Figure Legends from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supplementary Figure Legends

Figure 4S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 4 Detection of NK cells in vivo A, Representative Dot plots of gated live cells based on FSCÃ,ÂA and SSCÃ,ÂA and CD19+CD10+ cells in the bone marrow and spleen of NSG mice treated with PBS (left) or 2x106 PTÃ,Â3 ALL cells (ri…

Figure 5S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 5 EW-7197 treatment increases VAY736 induced NK cell mediated ADCC of ALL cells in vivo A, Mouse TGF-beta Elisa using serum from PBS or ALL (PT-3) i.v. injected mice on day 35. B, Normalized weight (spleen weight/mouse weight) a…

Supplementary Figure Legends from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supplementary Figure Legends

Figure 3S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 3 Differential NK cells receptor expression A, Expression of activating and inhibitory receptors in NK cells expanded from the indicated healthy donors (mean {plus minus} SD of 3 technical replicates). B, Expression of HLAE and …

Figure 6S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 6 EW-7197 treatment increases VAY736 induced NK cell mediated ADCC of ALL cells in vivo A, Percentages of CD16+ NK cells in bone marrow and spleen of mice from Figure.6C-E. B, Normalized weight in grams (spleen weight/mouse weig…

Data from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies. Our study exploited the presence of B-cell activating factor receptor (BAFF-…

Figure 2S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia Open

Yorleny Vicioso, Hermann Gram, Rose Beck, Abhishek Asthana, Keman Zhang , et al. · 2023

Supp. Fig. 2 BAFF induces up-regulation of survival pathways. A, PT-3 ALL cells were cultured with VAY736 (20 ÃŽÂ¼g/mL) and recombinant BAFF (0.2 ÃŽÂ¼g/mL) for 72 hours and the expression levels of proliferation genes (p100, p52) and survi…

Figure S1 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

Comparative expression of genes involved in O-GlcNAcylation.

Data from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

Treatment for acute myeloid leukemia (AML) has remained unchanged for past 40 years. Targeting cell metabolism is a promising avenue for future cancer therapy. We found that enzymes involved in metabolic hexosamine biosynthetic pathway (HB…

Figure S2 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

DON reduces proliferation and induces apoptosis.

Figure S6 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

Hematological profile after In vivo DON administration.

Supplementary Materials & Methods from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

Supplementary Materials & Methods

Figure S5 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

In vivo evaluation of DON administration.

Figure S1 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

Comparative expression of genes involved in O-GlcNAcylation.

Figure S4 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

siRNA mediated OGT silencing reduces proliferation and induce apoptosis.

Figure S3 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

HBP inhibition affects phosphorylation of target protein, expression of transcription factors and cause minor change in cellular metabolism.

Data from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

Treatment for acute myeloid leukemia (AML) has remained unchanged for past 40 years. Targeting cell metabolism is a promising avenue for future cancer therapy. We found that enzymes involved in metabolic hexosamine biosynthetic pathway (HB…

Figure S3 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

HBP inhibition affects phosphorylation of target protein, expression of transcription factors and cause minor change in cellular metabolism.

Figure S2 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

DON reduces proliferation and induces apoptosis.

Figure S5 from Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death Open

Abhishek Asthana, Parameswaran Ramakrishnan, Yorleny Vicioso, Keman Zhang, Reshmi Parameswaran · 2023

In vivo evaluation of DON administration.

Fetching topic information...